KETOROLAC JUNO ketorolac trometamol 30 mg/1 mL solution for injection ampoule Australia - English - Department of Health (Therapeutic Goods Administration)

ketorolac juno ketorolac trometamol 30 mg/1 ml solution for injection ampoule

juno pharmaceuticals pty ltd - ketorolac trometamol, quantity: 30 mg - injection, solution - excipient ingredients: sodium hydroxide; sodium chloride; water for injections; ethanol - ketorolac trometamol solution for injection is indicated for the short-term management of moderately severe, acute pain following surgical procedures. the total duration of ketorolac use should not exceed five days.,it is recommended that ketorolac parenteral be used in the immediate post-operative period.,patients can then be converted to the oral formulation (dependent on their analgesic needs), as outlined in the "dosage and administration" section (refer to "conversion from parenteral to oral therapy"). the total period of treatment utilising the oral and/or intramuscular route of administration is not to exceed five days. note that oral dosage form can be available from other brand/s.,general,ketorolac trometamol solution for injection is not recommended for use as an obstetrical pre-operative medication or for obstetrical analgesia because it has not been adequately studied for use in these circumstances and because the known effects of drugs that inhibit prostaglandin biosynthesis on uterine contraction and foetal circulation.,there is no satisfactory evidence for the use of ketorolac trometamol solution for injection in acute exacerbations of chronic painful inflammatory conditions (e.g. rheumatoid or osteoarthritis).

KETOROLAC-BAXTER ketorolac trometamol 30 mg/1 mL solution for injection ampoule Australia - English - Department of Health (Therapeutic Goods Administration)

ketorolac-baxter ketorolac trometamol 30 mg/1 ml solution for injection ampoule

baxter healthcare pty ltd - ketorolac trometamol, quantity: 30 mg/ml - injection, solution - excipient ingredients: ethanol; sodium hydroxide; hydrochloric acid; nitrogen; water for injections; sodium chloride - ketorolac-baxter is indicated for the short-term management of moderately severe, acute pain following surgical procedures. the total duration of ketorolac use should not exceed five days.,it is recommended that ketorolac parenteral be used in the immediate post-operative period. patients can then be converted to the oral formulation (dependent on their analgesic needs), as outlined in section 4.2 dose and method of administration (refer to "conversion from intramuscular to oral therapy"). the total period of treatment utilising the oral and/or intramuscular route of administration is not to exceed five days.,general,ketorolac-baxter is not recommended for use as an obstetrical pre-operative medication or for obstetrical analgesia because it has not been adequately studied for use in these circumstances and because the known effects of drugs that inhibit prostaglandin biosynthesis on uterine contraction and foetal circulation.,there is no satisfactory evidence for the use of ketorolac-baxter in acute exacerbations of chronic painful inflammatory conditions (e.g. rheumatoid or osteoarthritis).

KETOROLAC-BAXTER ketorolac trometamol 10 mg/1 mL solution for injection ampoule Australia - English - Department of Health (Therapeutic Goods Administration)

ketorolac-baxter ketorolac trometamol 10 mg/1 ml solution for injection ampoule

baxter healthcare pty ltd - ketorolac trometamol, quantity: 10 mg/ml - injection, solution - excipient ingredients: sodium chloride; ethanol; nitrogen; water for injections; hydrochloric acid; sodium hydroxide - ketorolac-baxter is indicated for the short-term management of moderately severe, acute pain following surgical procedures. the total duration of ketorolac use should not exceed five days.,it is recommended that ketorolac parenteral be used in the immediate post-operative period. patients can then be converted to the oral formulation (dependent on their analgesic needs), as outlined in section 4.2 dose and method of administration (refer to "conversion from intramuscular to oral therapy"). the total period of treatment utilising the oral and/or intramuscular route of administration is not to exceed five days.,general,ketorolac-baxter is not recommended for use as an obstetrical pre-operative medication or for obstetrical analgesia because it has not been adequately studied for use in these circumstances and because the known effects of drugs that inhibit prostaglandin biosynthesis on uterine contraction and foetal circulation.,there is no satisfactory evidence for the use of ketorolac-baxter in acute exacerbations of chronic painful inflammatory conditions (e.g. rheumatoid or osteoarthritis).

KETOROLAC KABI ketorolac trometamol 30 mg/1 mL solution for injection, vial Australia - English - Department of Health (Therapeutic Goods Administration)

ketorolac kabi ketorolac trometamol 30 mg/1 ml solution for injection, vial

fresenius kabi australia pty ltd - ketorolac trometamol, quantity: 30 mg/ml - injection, solution - excipient ingredients: ethanol; sodium chloride; water for injections; hydrochloric acid; sodium hydroxide - ketorolac kabi is indicated for the short-term management of moderately severe, acute pain following surgical procedures. the total duration of ketorolac use should not exceed five days.,it is recommended that ketorolac parenteral be used in the immediate post-operative period. patients can then be converted to the oral formulation (dependent on their analgesic needs), as outlined in the "dose and method of administration" section (refer to "conversion from parenteral to oral therapy"). the total period of treatment utilising the oral and/or intramuscular route of administration is not to exceed five days.,general,ketorolac is not recommended for use as an obstetrical pre-operative medication or for obstetrical analgesia because it has not been adequately studied for use in these circumstances and because the known effects of drugs that inhibit prostaglandin biosynthesis on uterine contraction and foetal circulation.,there is no satisfactory evidence for the use of ketorolac in acute exacerbations of chronic painful inflammatory conditions (e.g. rheumatoid or osteoarthritis).

KETOROLAC MEDSURGE ketorolac trometamol 10 mg/1 mL solution for injection ampoule Australia - English - Department of Health (Therapeutic Goods Administration)

ketorolac medsurge ketorolac trometamol 10 mg/1 ml solution for injection ampoule

medsurge pharma pty ltd - ketorolac trometamol, quantity: 10 mg - injection - excipient ingredients: sodium chloride; sodium hydroxide; water for injections; hydrochloric acid; ethanol - ketorolac medsurge solution for injection is indicated for the short-term management of moderately severe, acute pain following surgical procedures. the total duration of ketorolac use should not exceed five days. it is recommended that ketorolac parenteral be used in the immediate post-operative period. patients can then be converted to the oral formulation (dependent on their analgesic needs), as outlined in the section 4.2 dose and method of administration (refer to conversion from parenteral to oral therapy). the total period of treatment utilising the oral and/or intramuscular route of administration is not to exceed five days. note that oral dosage forms are available from other brands.,general,ketorolac medsurge solution for injection is not recommended for use as an obstetrical pre-operative medication or for obstetrical analgesia because it has not been adequately studied for use in these circumstances and because the known effects of drugs that inhibit prostaglandin biosynthesis on uterine contraction and foetal circulation.,there is no satisfactory evidence for the use of ketorolac medsurge solution for injection in acute exacerbations of chronic painful inflammatory conditions (e.g. rheumatoid or osteoarthritis).

KETOROLAC MEDSURGE ketorolac trometamol 30 mg/1 mL solution for injection ampoule Australia - English - Department of Health (Therapeutic Goods Administration)

ketorolac medsurge ketorolac trometamol 30 mg/1 ml solution for injection ampoule

medsurge pharma pty ltd - ketorolac trometamol, quantity: 30 mg - injection - excipient ingredients: sodium chloride; ethanol; sodium hydroxide; hydrochloric acid; water for injections - ketorolac medsurge solution for injection is indicated for the short-term management of moderately severe, acute pain following surgical procedures. the total duration of ketorolac use should not exceed five days. it is recommended that ketorolac parenteral be used in the immediate post-operative period. patients can then be converted to the oral formulation (dependent on their analgesic needs), as outlined in the section 4.2 dose and method of administration (refer to conversion from parenteral to oral therapy). the total period of treatment utilising the oral and/or intramuscular route of administration is not to exceed five days. note that oral dosage forms are available from other brands.,general,ketorolac medsurge solution for injection is not recommended for use as an obstetrical pre-operative medication or for obstetrical analgesia because it has not been adequately studied for use in these circumstances and because the known effects of drugs that inhibit prostaglandin biosynthesis on uterine contraction and foetal circulation.,there is no satisfactory evidence for the use of ketorolac medsurge solution for injection in acute exacerbations of chronic painful inflammatory conditions (e.g. rheumatoid or osteoarthritis).

KETOROLAC APOTEX ketorolac trometamol 30 mg/1 mL solution for injection ampoule Australia - English - Department of Health (Therapeutic Goods Administration)

ketorolac apotex ketorolac trometamol 30 mg/1 ml solution for injection ampoule

apotex pty ltd - ketorolac trometamol -

KETOROLAC APOTEX ketorolac trometamol 10 mg/1 mL solution for injection ampoule Australia - English - Department of Health (Therapeutic Goods Administration)

ketorolac apotex ketorolac trometamol 10 mg/1 ml solution for injection ampoule

apotex pty ltd - ketorolac trometamol -

KETOROLAC TROMETAMOL ROMPHARM 30 MGML Israel - English - Ministry of Health

ketorolac trometamol rompharm 30 mgml

a.l. medi-market ltd. - ketorolac trometamol - solution for injection - ketorolac trometamol 30 mg / 1 ml - ketorolac - ketorolac trometamol 30 mg/ml, solution for injection is indicated for the short-term management of moderate to severe acute post-operative pain. the maximum duration of treatment is two days.

KETORAL ketorolac trometamol 30mg/1mL injection syringe Australia - English - Department of Health (Therapeutic Goods Administration)

ketoral ketorolac trometamol 30mg/1ml injection syringe

alphapharm pty ltd - ketorolac trometamol, quantity: 30 mg - injection, solution - excipient ingredients: sodium chloride; hydrochloric acid; ethanol; sodium hydroxide; water for injections - short-term management of moderately severe, acute pain following surgical procedures. the total duration of ketorolac use should not exceed five days. it is recommended that parenteral ketorolac be used in the immediate postoperative period. patients can then be converted to an oral formulation (dependent on their analgesic needs). see dosage and administration, conversion from parenteral to oral therapy. the total period of treatment utilising the oral and/or intramuscular route of administration is not to exceed five days. general ketoral is not recommended for use as an obstetric preoperative medication or for obstetric analgesia because it has not been adequately studied for use in these circumstances and because of the known effects of drugs that inhibit prostaglandin biosynthesis on uterine contraction and fetal circulation. there is no satisfactory evidence for the use of ketoral in acute exacerbations of chronic painful inflammatory conditions (e.g. rheumatoid arthritis or osteoarthritis).